Literature DB >> 27713614

Using Rivaroxaban as Thrombolytic Treatment for a Patient of Pedal Arch Arterial Thrombosis with Suboptimal Result of Endovascular Therapy.

Hsin-Fu Lee1, Yi-Hsin Chan2, Chun-Li Wang2.   

Abstract

A 77-year-old male with subacute right foot ischemia was treated with endovascular therapy to relieve total thrombosis of the pedal arch extending from the dorsalis pedis of the anterior tibial artery into the posterior tibial artery, plantar segment. Because the procedure was only partially successful, rivaroxaban was used for thrombolytic treatment resulting in improvement of the patient's ischemic pain and avoidance of gangrenous progression and surgical amputation. This is the first report describing successful recanalization of pedal arch arterial thrombosis using rivaroxaban in a patient after suboptimal results of endovascular therapy.

Entities:  

Keywords:  Arterial thrombosis; Endovascular therapy; Rivaroxaban

Year:  2016        PMID: 27713614      PMCID: PMC5052484          DOI: 10.6515/acs20151229a

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  9 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.

Authors:  Nana-Maria Wagner; Tobias Dressel; Katrin Schäfer; Stavros Konstantinides
Journal:  Thromb Res       Date:  2012-01-26       Impact factor: 3.944

3.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

4.  Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.

Authors:  Tom J Parry; Zhihong Huang; Cailin Chen; Margery A Connelly; Elisabeth Perzborn; Patricia Andrade-Gordon; Bruce P Damiano
Journal:  Blood Coagul Fibrinolysis       Date:  2011-12       Impact factor: 1.276

5.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

Review 6.  Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulation.

Authors:  Alexander G G Turpie; Charles Esmon
Journal:  Thromb Haemost       Date:  2011-01-12       Impact factor: 5.249

Review 7.  Triggers, targets and treatments for thrombosis.

Authors:  Nigel Mackman
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

8.  Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Shaun G Goodman; Venu Menon; Christopher P Cannon; Gabriel Steg; E Magnus Ohman; Robert A Harrington
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 9.  Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases.

Authors:  Anetta Undas; Robert A S Ariëns
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-11       Impact factor: 8.311

  9 in total
  2 in total

1.  Long term efficacy and safety of rivaroxaban plus cilostazol in the treatment of critical ischemia of the lower limbs in a frail, elderly patient with non valvular atrial fibrillation.

Authors:  Antonio Trani; Pietro Benedetto; Ferdinando Di Leo; Angela Baiano; Andrea Esposito; Danilo Menna; Arianna Allegretti; Pierluigi Antonino Cappiello; Domenico Dell'Edera
Journal:  J Pharm Health Care Sci       Date:  2020-08-03

2.  Endovascular and Hybrid Revascularization for Complicated Aorto-Iliac Occlusive Disease: Short-Term Results in Single Institute Experience.

Authors:  Tai-Wei Chen; Chun-Yang Huang; Po-Lin Chen; Chiu-Yang Lee; Chun-Che Shih; I-Ming Chen
Journal:  Acta Cardiol Sin       Date:  2018-07       Impact factor: 2.672

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.